PHYSIOLYTE IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PHYSIOLYTE IN PLASTIC CONTAINER (PHYSIOLYTE IN PLASTIC CONTAINER).
Physiolyte is an isotonic crystalloid solution that provides electrolytes and water to maintain or restore intravascular volume and correct fluid and electrolyte imbalances. The mechanism involves distribution of fluids between intravascular and interstitial spaces, with electrolytes contributing to osmotic balance and physiological functions.
| Metabolism | The components of Physiolyte (sodium, chloride, potassium, calcium, magnesium, and acetate) are not metabolized; they are excreted primarily by the kidneys. Acetate is rapidly metabolized in the liver to bicarbonate. |
| Excretion | Physiolyte is a balanced crystalloid solution; its components (electrolytes and water) are excreted primarily via renal elimination. Water is eliminated by kidneys (urine), lungs (insensible loss), and skin (sweat). Electrolytes (Na+, K+, Ca2+, Mg2+, Cl-, acetate, gluconate) are predominantly excreted renally with minimal biliary or fecal elimination (<5%). |
| Half-life | The terminal elimination half-life of the infused crystalloid components is not applicable as a single value; the half-life of water is approximately 30–60 minutes in healthy individuals, but varies with renal function. Electrolytes have longer half-lives (e.g., Na+ ~12–24 hours). Clinical context: In renal impairment, half-life is prolonged. |
| Protein binding | The components of Physiolyte (electrolytes) do not significantly bind to plasma proteins; protein binding is negligible (<5%). |
| Volume of Distribution | Volume of distribution for crystalloid solutions is approximately 0.2–0.25 L/kg for water and electrolytes, corresponding to the extracellular fluid volume. Clinical meaning: Rapid redistribution from intravascular to interstitial space (about 75% leaves vasculature within 1 hour). |
| Bioavailability | Intravenous: 100% bioavailability. Not administered orally. |
| Onset of Action | Intravenous: Onset of action is immediate upon infusion for volume expansion and electrolyte correction; clinical effects (hemodynamic changes) occur within minutes. |
| Duration of Action | Intravenous: Duration of volume expansion is approximately 1–2 hours due to redistribution and renal excretion; electrolyte effects persist as long as infusion continues or until renal excretion balances intake. |
Intravenous infusion; dose determined by clinical condition (e.g., dehydration, electrolyte replacement). Typical adult: 500–1000 mL as a single infusion; rate based on clinical status.
| Dosage form | SOLUTION |
| Renal impairment | No specific dose adjustment; use with caution in renal impairment due to risk of fluid/electrolyte overload. Monitor serum electrolytes and renal function. |
| Liver impairment | No specific dose adjustment; use with caution in hepatic impairment due to potential fluid/electrolyte imbalances. |
| Pediatric use | Intravenous infusion; dose determined by weight and clinical condition. Typical: 20–30 mL/kg as a single infusion; adjust based on ongoing losses and maintenance requirements. |
| Geriatric use | Use with caution due to increased risk of fluid overload and electrolyte disturbances; monitor renal function and fluid status; adjust rate and volume as needed. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PHYSIOLYTE IN PLASTIC CONTAINER (PHYSIOLYTE IN PLASTIC CONTAINER).
| Breastfeeding | Physiolyte is an electrolyte solution; its components are normal constituents of breast milk. M/P ratio not applicable. Considered compatible with breastfeeding. |
| Teratogenic Risk | Physiolyte is a balanced electrolyte solution. No teratogenic effects reported. Considered low risk in all trimesters when used as directed. |
| Fetal Monitoring |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to any component","Severe renal impairment (anuria or oliguria)","Hyperkalemia (for solutions containing potassium)","Hypermagnesemia (for solutions containing magnesium)","Hypercalcemia (for solutions containing calcium)","Severe metabolic alkalosis","Concurrent administration with certain drugs that may cause adverse interactions (e.g., potassium-sparing diuretics, ACE inhibitors)"]
| Precautions | ["Use with caution in patients with congestive heart failure, renal impairment, or conditions that may cause fluid overload","Monitor serum electrolytes, fluid balance, and renal function during therapy","Not recommended for use in neonates or infants without careful monitoring due to risk of hypernatremia","Avoid rapid or large-volume infusions in patients with compromised cardiovascular or renal function"] |
Loading safety data…
| Monitor serum electrolytes, fluid balance, and renal function. In pregnancy, monitor for signs of fluid overload or electrolyte imbalance. |
| Fertility Effects | No known effects on fertility at standard doses. |